Prohost Letter #430
Rheumatoid Arthritis and Gilead
The FINCH 1 trial: Has it reached its primary endpoints? How did the drugs respond as compared to placebo; what is the disability index, clinical remission, disease activity rate and safety results? What’s happening with Gilead’s HIV product? Read about Gilead’s collaboration with Galapagos. See how Prohost answers these questions in this issue #430 of the Prohost Letter.
Novartis, Novartis, Novartis
The IFM Tre acquisition, inflammatory and autoimmune diseases; MS & Mayzent; genetic engineering, SMA and AveXis’ new facility. Read about Novartis' revolution and Prohost . . .
This content is for paid subscribers.
Prohost Letters April 5, 2019